ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Altimmune Inc (ALT) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has bearish technical indicators, and no recent Intellectia Proprietary Trading Signals. While analysts maintain a generally positive outlook with high price targets, the long-term nature of the catalysts (e.g., Phase 3 study results in 2029) and current bearish trends suggest holding off on investment for now.
The technical indicators for ALT are bearish. The MACD histogram is below 0 and negatively contracting, RSI is neutral at 51.01, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 2.714, with resistance at 2.847 and support at 2.58.
Analysts have maintained a Buy or Outperform rating with high price targets, citing the company's fully funded MASH program and differentiated metabolic dysfunction-associated steatohepatitis candidate. Recent financing has resolved near-term capital constraints.
The stock has no recent news or significant trading trends from hedge funds or insiders. Bearish technical indicators and a lack of short-term catalysts weigh on the stock. The key Phase 3 study results are not expected until 2029, making it a long-term play.
No financial data is available for the latest quarter.
Analysts have lowered price targets recently but maintain a positive outlook. H.C. Wainwright lowered the target to $20 from $25, and Citizens lowered it to $11 from $14, both retaining Buy or Outperform ratings. Goldman Sachs upgraded the stock to Neutral from Sell, with a price target increase to $2.50 from $1.
